SEC Form 4 · accession 0001237899-17-000010
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A Baker
Director
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $376.69 | Jan 3, 2017 | A | 7,830 | A | — | Jan 3, 2027 | Common Stock | 7,830 | 7,830 | D |
Explanation of responses
- F1The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.